Biomarin Pharmaceutical Inc (BMRN) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.

Total Assets Chart for Biomarin Pharmaceutical Inc

Biomarin Pharmaceutical Inc (BMRN) total assets for FY2025 were USD 7.6B, a 8.7% change from FY2024. Biomarin Pharmaceutical Inc's total assets grew from USD 31.5M in 1998 to USD 7.6B in 2025 (24000.4% over 27 years). Total assets compound annual growth rate: 5-year CAGR of 5.4%, 10-year CAGR of 7.4%, 20-year CAGR of 20.1%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$10.88B
Implied Share Price
$56.22
Enterprise Value
$15.37B
Revenue (TTM)
$3.41B
EBITDA
$645.32M
Profit Margin
2.14%
Trailing P/E
151.95
Forward P/E
9.40
Price/Book (MRQ)
1.90
Price/Sales (TTM)
3.19
EV/EBITDA
39.85
EV/Revenue
4.51
Dividend Yield
—
Book Value
$32.66
Free Cash Flow (FY2025)
$724.96M
Free Cash Flow Yield
6.66%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.